Posting of J&A - Production of Therapeutic (casirivimab and imdevimab) in Support of National Emergency Response to Coronavirus 2019 (COVID-19)

Awarded Limited / Sole Source Justification Posted

See its 2 award notices in the notice history.

Solicitation number
W15QKN-21-C-0014
Agency
Set-aside
No set-aside

Opportunity facts

Contract number
W15QKN-21-C-0014 Federal contract award

Notice details come from SAM.gov. Updated .

About this opportunity

Written by GovTribe AI ·

This Limited/Sole Source Justification Notice from the Department of the Army Materiel Command Contracting Command Picatinny Arsenal was executed to support the production of therapeutic monoclonal antibodies (casirivimab and imdevimab) in response to the COVID-19 national emergency. The justification and approval was conducted in accordance with FAR 6.305(b) for a sole source award of an unknown amount to an unknown vendor under contract number W15QKN-21-C-0014 on January 12, 2021 to rapidly produce these antibodies to treat COVID-19 and help combat the virus, as the vendor is the only known source able to immediately satisfy the agency's requirements.

Notice text

The posting of this Justification & Approval (J&A) is executed in accordance with FAR 6.305(b).

Awarded contract W15QKN-21-C-0014 to unknown vendor for unknown amount on 2021-01-12.

Files

File Type Posted
REDACTED JA Antibody Therapeutics COVID-19 REGENERON_FOR RELEASE.pdf PDF

Notice history

Notice Type Posted
Production of an Additional 1. 4M Doses of REGEN-COV Latest Award Notice
This notice Limited / Sole Source Justification
Production of Therapeutic (casirivimab and imdevimab) in Support of National Emergency Response to Coronavirus 2019 (COVID-19) Original Award Notice

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity
Try for free Login

GovTribe for Federal Contractors